Korea Biomedical Review | 2024-06-27

Mediwhale, a medical AI diagnostic solution provider, said Thursday that it has been selected as a “JLABS” company, benefitting from a global accelerator platform operated by Johnson & Johnson Innovation, a multinational pharmaceutical giant.

Mediwhale’s “Dr. Eye (Reti-CVD)” (Courtesy of Mediwhale)
JLABS picks companies through a rigorous, months-long evaluation process. Selected companies will have access to a broad range of expertise, research advice, and global networks across the pharmaceutical and medical technology sectors from JLABS offices worldwide.

JLABS is a specialized accelerator organization under Johnson & Johnson with locations in 11 regions (seven in North America, one in Europe, and three in Asia). This year, it established JLABS Korea, which was selected to operate the Ministry of Health and Welfare’s global accelerator platform to help Korean biopharmaceutical and medical device companies accelerate their access to global markets.

“We will use this opportunity to accelerate our global expansion by leveraging Johnson & Johnson’s best-in-class global network and know-how,” Mediwhale CEO Choi Tae-geun said. “First, we will actively utilize JLABS for the global commercialization of “Dr. Eye” (Reti-CVD), which predicts cardiovascular disease through simple retinal imaging.”

Choi continued, “We will strengthen our pipeline of products that predict cardiovascular and metabolic diseases through retinal blood vessels, and work closely with pharmaceutical companies in kidney disease and cerebrovascular disease prediction, which are becoming increasingly important.”

Mediwhale’s Dr.Eye (Reti-CVD) was chosen as a deferred evaluation new medical technology in June last year and is prescribed at many hospitals, including Yonsei University Health System, a top-tier general hospital in Korea, on a non-reimbursement basis.

This year, Mediwhale is expanding its supply to major university hospitals, screening centers, and private clinics, and aims to launch in the U.S. in early 2026.

출처 : KBR(https://www.koreabiomed.com)